S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Price Target & Analyst Ratings

$0.34
-0.02 (-5.62%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.32
▼
$0.37
50-Day Range
$0.33
▼
$0.62
52-Week Range
$0.32
▼
$64.40
Volume
697,030 shs
Average Volume
740,256 shs
Market Capitalization
$5.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Panbela Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$10.00
2,876.19% Upside
High Prediction$10.00
Average Prediction$10.00
Low Prediction$10.00
TypeCurrent
5/27/22 to 5/27/23		1 Month Ago
4/27/22 to 4/27/23		3 Months Ago
2/26/22 to 2/26/23		1 Year Ago
5/27/21 to 5/27/22
Consensus Rating
Buy
Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.00$7.50$7.50$9.33
Predicted Upside2,876.19% Upside359.35% Upside359.35% Upside263.04% Upside
Get Panbela Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.


PBLA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PBLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Panbela Therapeutics Stock vs. The Competition

TypePanbela TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside2,876.19% Upside1,394.30% Upside186.86% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/26/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Pantginis
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
3/20/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy
1/31/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$10.00+506.79%
(Data available from 5/27/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PBLA Price Target - Frequently Asked Questions

What is Panbela Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Panbela Therapeutics stock is Buy based on the current 3 buy ratings for PBLA. The average twelve-month price prediction for Panbela Therapeutics is $10.00 with a high price target of $10.00 and a low price target of $10.00. Learn more on PBLA's analyst rating history.

Do Wall Street analysts like Panbela Therapeutics more than its competitors?

Analysts like Panbela Therapeutics more than other Medical companies. The consensus rating score for Panbela Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how PBLA compares to other companies.

Is Panbela Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, Panbela Therapeutics's stock had 1 upgrade by analysts.

Does Panbela Therapeutics's stock price have much upside?

According to analysts, Panbela Therapeutics's stock has a predicted upside of 506.80% based on their 12-month price targets.

What analysts cover Panbela Therapeutics?

Panbela Therapeutics has been rated by HC Wainwright, and Maxim Group in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:PBLA) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -